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Aim: To evaluate proton-beam radiotherapy (PBRT) in the management of uveal melanoma 
in Scotland.
Methods: A retrospective review was undertaken on all patients receiving PBRT for uveal 
melanoma (1994–2005). Data obtained included: gender, past ocular/medical history, age, 
presenting complaint(s), diagnosis, laterality, tumor location/ultrasound characteristics, visual 
acuity (VA) and intraocular pressure. At post-treatment reviews (3, 6, 12, and 24 months), 
the following data was obtained: VA, intraocular pressure, tumor appearance and ultrasound 
characteristics. Mean follow up was 38.8 months.
Results: Seventy-six patients were included. Mean age was 64 years; male to female ratio was 
1.1:1. Ninety-seven percent demonstrated initial treatment response; 87% had successful control 
of tumor growth. Mean pre-treatment tumor height was 6.2 mm v.s. 4.8 mm post-irradiation 
(p  0.001). Pre-irradiation VA was 3/60 in 18.5% compared with 74% post-irradiation 
(p  0.0001). There was a statistically signiﬁ  cant association between adverse events (enucle-
ation, metastasis) and greater maximal basal tumor diameter. Eighteen eyes were enucleated. 
The median survival time was estimated to be 54 months.
Conclusion: In our experience, PBRT is a precise, reliable and effective treatment in the 
management of large, and previously treated uveal melanomas. It prevents enucleation in the 
majority at short term follow-up.
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Introduction
Uveal melanoma is the most common primary adult ocular malignancy1–5 with an incidence 
of 0.6/100,000.1 It is the only potentially fatal intraocular tumor in the adult.2
The standard treatment of choroidal melanoma used to be primary enucleation.4–6 
Zimmerman7 in the 1970’s suggested this may not be the best management. Globe 
preserving management is now favored. Such techniques include: laser photocoagula-
tion,1,8,9 transpupillary thermotherapy,1,8,10 local resection, radiotherapy (charged particle 
or brachytherapy) and, most recently, the gamma knife.11, 12 Enucleation is reserved 
for an end stage disease.
Proton-beam radiotherapy (PBRT) was ﬁ  rst utilized in the management of uveal 
melanoma in 1975.13 It is now predominantly used for choroidal and ciliary body 
melanomas. Ocular complications may arise,2,5,14 such as radiation retinopathy, 
neuropathy and cataract.2,14 They are largely dependent on tumor size and location.2 This 
retrospective study was performed to evaluate the use of PBRT in the management of 
relatively large uveal melanoma and to review our treatment experience.
Methods
A retrospective case note review was performed on 76 patients who received PBRT for 
uveal melanoma. The diagnosis was established utilizing clinical examination features, Clinical Ophthalmology 2009:3 50
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photographs, and ultrasound ﬁ  ndings. Histopathological 
conﬁ  rmation was performed on all enucleation specimens. 
All patients were jointly managed at the Tennent Institute 
of Ophthalmology, Glasgow, Scotland (referral centre) and 
the Clatterbridge Centre for Oncology, Wirral, England 
(treatment centre).
Initially, some lesions underwent photocoagulation, local 
resection (medium sized equatorial lesions), or brachytherapy 
(maximal vertical tumor height [MVTH] of 5 mm) when 
they proved to be amenable to such modality of treatment. 
Multiple treatment failure was managed with enucleation. 
Patients were offered PBRT if their lesions were unsuitable 
for alternative treatments, if they demonstrated prior treat-
ment failure or had iris/ciliary body tumors.
All patients were assessed by the same consultant 
ophthalmologist (EGK) and had ultrasound examinations 
performed by three consultant radiologists. All patients had 
irradiation planning and treatment delivered by the same 
multidisciplinary team.
PBRT protocol
Stage one involved surgical placement of tantalum clips 
to demarcate the tumor periphery. Stage two incorporated 
the simulation and planning of patient speciﬁ  c treatment. 
Cranial X-rays, fundus photographs, and ocular ultrasound 
data were utilized to create computer-generated patient 
eye/tumor models. Clip positions were used at simulation to 
plan individualized irradiation ﬁ  elds. Stage three involved 
delivery of PBRT in four consecutive, daily fractions 
(30 seconds each) to a total dose of 53.1 protons Gray (58 Gy 
Co-60 equivalents).
The following data were obtained for each patient: 
gender, past ocular/medical history, age at presentation, 
presenting complaint(s), ocular diagnosis, laterality, 
anatomical tumor location, tumor ultrasound characteristics 
[(MVTH) and maximal basal tumor diameter (MBTD)], best 
corrected visual acuity (BCVA), intraocular pressure (IOP) 
and PBRT data (total dose, duration, number of fractions, 
maximum exposure dose to various ocular structures). At 
post-treatment review (3, 6, 12, and 24 months), the following 
data was obtained: BCVA, IOP, tumor appearance (clinical 
examination, fundus photography) and ultrasound charac-
teristics. The development of metastatic disease and patient 
mortality was documented. Tumor growth was monitored 
utilizing serial ultrasound examinations, clinical examina-
tion, and fundus photography. Treatment endpoints included 
evidence of tumor growth, enucleation, and patient death. 
The follow-up period was calculated from ﬁ  rst treatment 
date until documentation of tumor growth, enucleation, or 
last clinic visit.
Statistical analysis was performed using p-value for 
assessment of statistical signiﬁ  cance of tumor dimensions 
and changes in BCVA. Kaplan-Meier survival analysis 
was applied for assessment of the cumulative adverse event 
rate over time. The effects of baseline characteristics on 
subsequent adverse event rates were estimated using Cox 
proportion hazards models.
Results
Demographics
Seventy-six patients received PBRT for uveal melanoma 
between January 1994 and June 2005 (Table 1). Seventy 
had a clinical diagnosis of choroidal melanoma and six had 
presumed iris/ciliary body melanoma. Nine patients had 
previously received treatment: Ruthenium-106 plaque (n = 4), 
local tumor resection (n = 2), and laser photocoagulation 
(n = 3). Patients were followed up for a mean of 38.8 months 
(range 3–122).
Tumor growth
Seventy-four patients (97%) demonstrated an initial response 
to treatment (stabilization of tumor growth, with or without 
regression). There was evidence of continued tumor growth 
Table 1 Baseline characteristics
Age at treatment (years) Median (Range) 64 (29–88)
Sex Male 40 (53%)
Female 36 (47%)
Affected eye Right 40 (53%)
Left 36 (47%)
Presenting symptom(s) Blurred vision 35 (46%)
Asymptomatic 22 (28.9%)
Flashes and/or ﬂ  oaters 10 (13.2%)
Visual ﬁ  eld defect 5 (6.6%)
Others 4 (5.3%)
Tumor location Choroidal 70
Straddling equator 45 (59%)
Posterior to equator 25 (33%)
Iris/ciliary body 6
Subretinal ﬂ  uid Present 50 (66%)
Absent 26 (34%)
Referral source Optometrist 32 (42%)
Ophthalmologist 30 (39%)
GP 2 (3%)
Unknown 12 (16%)
Note: Number of patients (percentage of total) unless stated otherwise.Clinical Ophthalmology 2009:3 51
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2 months post treatment in both remaining patients, one 
with extension along the optic nerve. Sixty-six (87%) patients 
had successful control of tumor growth throughout the entire 
follow-up period. Ten (13%) demonstrated evidence of 
long-term treatment failure (no response to treatment [n = 2], 
delayed tumor progression [n = 4], development of metastatic 
disease [n = 4], of which one patient died during follow-up). 
Three (out of 10) demonstrated both tumor progression and 
metastatic disease.
Pre- and post-irradiation characteristics
In patients for whom both ultrasound measurements were 
available, there was a statistically signiﬁ  cant reduction in MVTH 
post treatment (N = 57; mean change, −1.65 mm; p  0.001) 
(Table 2). Fifty-one percent demonstrated a 1.5 mm decrease in 
height by one and a half years post-treatment. A reduced MBTD 
was also observed post-treatment, without reaching statistical 
signiﬁ  cance (N = 70; mean change, −0.52 mm; p = 0.072).
Visual acuity
Fourteen patients (18.5%) had a BCVA of 3/60 prior 
to radiotherapy compared with 56 (74%) afterwards 
(p  0.0001) (Table 2). Seven patients showed post-treatment 
improvement in BCVA. Tumors in these cases were located 
inferotemporally (n = 5), superonasally (n = 1), and at the 
posterior pole in the remaining patient. In this improved 
BCVA subgroup, the mean (SD) pre treatment MBTD was 
14 mm (2.4 mm) which reduced to 12.4 mm (1.2 mm) by 
the last visit. The mean (SD) MVTH was 6.0 mm (2.0 mm) 
and reduced to 4.4 mm (1.8 mm) by the last visit. Reduction 
in vision is mainly due to complications of treatment 
(42 patients, 55.2%).
Complications
The most common complication following PBRT was 
associated retinopathy. Rubeosis iridis was the second most 
common followed by cataract (Table 3).
Enucleation and metastasis
Eighteen patients (24%, 11 were male) underwent enucle-
ation during the follow-up period, of which 13 had associated 
retinal detachment. Indications for enucleation were: local 
tumor recurrence (n = 5), refractory glaucoma (n = 12), and 
optic nerve involvement (n = 1). Two patients had received 
prior treatment (laser and local resection). Enucleation was 
performed on average 22.3 months post-treatment.
Seven patients (four were male) developed clinically 
evident distant metastases during follow-up. One died from 
their disease during this period and one had histopathology 
conﬁ  rmed disease (liver biopsy). Three presented with clini-
cal evidence of distant metastases 11, 15, and 16 months post 
enucleation, respectively; two of these three patients showed 
initial tumor treatment response, the third did not. The 
remaining two patients developed clinically evident meta-
static disease 25 and 31 months post-PBRT, respectively.
The mean age at diagnosis of metastasis was 60 years. The 
mean (SD) MBTD for this subgroup was 12.2 mm (2.8 mm) and 
MVTH was 6.2 mm (1.9 mm). All had hepatic involvement; 
two also demonstrated breast and spleen metastases. Six had 
accompanying secondary retinal detachment prior to PBRT.
The duration from treatment date to development of ﬁ  rst 
adverse event (enucleation or late metastatic disease) or the 
end of follow-up was calculated for every patient; Figure 1 
shows the Kaplan-Meier estimate of the cumulative adverse 
event rate over time. The estimated survival at the maximal 
Table 2 Pre- and post-irradiation clinical characteristics
Pre-irradiation Post-irradiation Change (Post-Pre)
Mean  (SD) 
[N]
Mean  (SD) 
[N]
Mean (95% CI), 
p-value
Maximal tumor vertical height (mm) 6.2 (2.4)  [74] 4.8 (2.3)  [57] −1.65 (−2.32, −0.98), 
p  0.001
Maximal tumor basal diameter (mm) 11.7 (3.2)  [75] 11.2 (3.4)  [70] −0.52 (−1.10, 0.05), 
p = 0.072
N (%) N (%) Exact McNemar’s test 
p-value
Visual acuity 3/60 14 (18.5%) 56 (74%)
3/60–6/24 14 (18.5%) 3 (4%) 0.0001
6/18 48 (63%) 17 (22%)
Note: Mean changes not necessarily equal to differences between mean values, due to missing data.
Abbreviations: N, number of patients; SD, standard deviation.Clinical Ophthalmology 2009:3 52
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Table 3 Ocular complications of proton beam irradiation (multiple 
in some patients)
Complication Number of patients 
(% of total)
Retinopathy 30 (39%)
Rubeosis iridis 16 (21%)
Cataract 15 (20%)
Uveitis 13 (17%)
Optic neuropathy 12 (16%)
Maculopathy 3 (4%)
Keratopathy 1 (1%)
follow-up time was in excess of 50%, so that the median time 
until the ﬁ  rst adverse event could not be estimated from these 
data. However, the lower 95% conﬁ  dence boundary for the 
median survival time was estimated to be 54 months.
The effects of baseline characteristics on subsequent 
adverse event rates were estimated using Cox proportion 
hazards models. The results are presented in Table 4. The only 
association observed was an increased risk of adverse events in 
those with greater MBTD, with an estimated 14.1% increased 
hazard (95% CI 0.3–29.8, p = 0.045) for every 1 mm increase in 
basal diameter. This ﬁ  nding must be viewed with some caution, 
since several variables were tested in this way, and the observed 
association is of borderline statistical signiﬁ  cance.
Resolution of pre-treatment secondary 
retinal detachment
Secondary retinal detachment was present in 50 patients 
(66%) prior to irradiation treatment. All resolved during 
follow up, 46% within the ﬁ  rst 3 months. Resolution of the 
detachment was noted prior to tumor regression.
Discussion
Proton beam irradiation treatment for uveal melanoma offers 
several advantages over other methods.6,15 It is a precise and 
reliable technique which achieves excellent tumor-normal 
tissue dose ratio.6,8,14–16 The density of ionization of protons 
increases markedly near the end of their path (Bragg peak). 
This characteristic enables accurate treatment, especially 
important for lesions close to vital ocular structures.6,14,16 
No handling of radioactive material is required by ophthal-
mologists dealing with PBRT, in contrast to brachytherapy 
where handling is required.8 External beam radiotherapy with 
photons will always result in less favorable dose distribution 
than PBRT.17 It appears that the use of gamma-knives leads 
to higher enucleation rate.18
Demographics
The average patient age in this study population was slightly 
higher than other reports.6,10,19–21 Age however, was not found 
to be associated with treatment failure in our study (P = 0.47) 
and by others.8
Women with uveal melanoma have previously been found 
to have more favorable outcomes than men.8 This was not 
duplicated in our study, possibly due to relatively limited 
follow up time.
Growth
Local control of disease is deﬁ  ned as clinical evidence of 
cessation of tumor growth or evidence of tumor regression.4 
Months
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Figure 1 Kaplan-Meier estimated cumulative adverse event rate (enucleation or distant metastasis) compared with follow-up time after proton beam irradiation.Clinical Ophthalmology 2009:3 53
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In this cohort, 87% demonstrated this following PBRT. 
Ultrasound examination revealed a statistically signiﬁ  cant 
decrease (p  0.001) in MVTH following treatment in the 
last visit. Other studies have shown less dramatic changes in 
tumor dimensions post-treatment.22 The degree of regression 
response did not appear to be related to initial tumor size in 
this study. This ﬁ  nding is similar to previous reports.19 Most 
of the treated tumors showed complete or partial regression 
after the ﬁ  rst 6 months of treatment, with a usual range 
between 1 and 24 months.19
Proton beam radiotherapy is an ocular-conserving option 
that may be considered for the treatment of extra-large uveal 
melanoma in carefully selected patients.17,21
Visual acuity
Visual acuity deteriorated post-treatment in most patients. 
Almost two thirds had a pre-treatment BCVA of 6/18 
compared with almost three quarters having BCVA of 3/60 
post-treatment, (P  0.0001, McNemar’s test). This was 
most likely due to direct radiation damage of vital visual 
structures. This level of acuity still enables spatial awareness 
perception, otherwise not present in enucleation cases. 
Other studies have shown higher levels of retained BCVA 
post-PBRT.4,10,23 It is difﬁ  cult to compare study outcomes 
due to variable pre-irradiation VA levels, anatomical sites 
of the tumors, irradiation doses, and variable complications 
of treatment.
Male gender has been associated with poorer final 
BCVA.5 This result was not reproduced in our study.
Complications
Thirty nine percent of our study population developed 
radiation retinopathy, higher than previously reported.15,21,24 
Proton beam-induced retinal ischemia predisposes to rubeosis 
iridis. Twenty one percent of our population developed 
this complication, Conway and colleagues showed higher 
rates.21 Rubeosis iridis resulting in secondary refractory 
glaucoma was the most common indication for enucleation 
in our study, this finding is similar to other reports in the 
literature.14 Tumor-induced angiogenic factors, inflam-
mation secondary to necrosis of the melanoma, retinal 
detachment, and ischemic retina and iris from irradiation 
are possible stimuli.25 The presence of subretinal fluid was 
not a significant risk factor in this study for the develop-
ment of neovascular glaucoma. Similar findings have 
been reported by Kim and colleagues.26 More recently 
Gragoudas and Lane found that larger tumor volume is 
the most significant factor associated with iris neovas-
cularisation.27 A similar finding was reported by Foss.14 
The early detection of neovascular glaucoma is important 
in the management of patients with uveal melanoma.28 
Rubeosis and neovascular glaucoma can be reduced 
when the anterior segment is spared.25 With a very sharp 
Bragg peak of proton beam, however the irradiation of 
the anterior segment could be reduced; it resulted in a 
lower number of anterior segment complications requiring 
enucleation.29
Resolution of pre-treatment secondary 
retinal detachment
Secondary retinal detachment resolved clinically in all cases 
prior to the evidence of tumor regression post-treatment. This 
ﬁ  nding has been conﬁ  rmed by a previous study.19 Secondary 
retinal detachments have been documented to develop after 
PBRT. None of our patients developed this. These have also 
been shown to resolve completely over time.21
Table 4 Estimated effects of baseline characteristics on adverse event rates following treatment with proton beam irradiation–hazard 
ratios with 95% conﬁ  dence intervals and p-values
Characteristic Effect Hazard ratio (95% CI) p-value
Age 60 vs 60 years 0.71 (0.27, 1.83) 0.47
/10 years (linear trend) 1.16 (0.80, 1.67) 0.43
Sex Male vs female 1.21 (0.51, 2.88) 0.66
Affected eye Right vs left 1.13 (0.48, 2.67) 0.79
Maximal basal tumor diameter 10 vs 10 mm 1.73 (0.67, 4.49) 0.26
/mm (linear trend) 1.14 (1.00, 1.30) 0.045
Maximal vertical tumor height 6 vs 6 mm 1.54 (0.65, 3.69) 0.33
/mm (linear trend) 1.11 (0.94, 1.32) 0.22
Subretinal ﬂ  uid Present vs absent 2.01 (0.74, 5.52) 0.17Clinical Ophthalmology 2009:3 54
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Enucleation
Secondary glaucoma and tumor growth were found to be 
the leading causes for enucleation following PBRT, both in 
this study and others.30 The post-irradiation enucleation rate 
in our study (18/76, 24%) was higher than that previously 
reported by some groups4,8,14,23,30,31 and lower than that 
reported by others (Table 5).21,24 A higher probability of 
enucleation (46%) has been shown for very large tumors.21,29 
Enucleation was performed on average 22.3 months post-
treatment, which was slightly longer than demonstrated 
by Kodjikian and colleagues8 and shorter than reported 
by Finger.4 The presence of retinal detachment prior to 
PBRT has been shown to be a signiﬁ  cant risk factor for 
subsequent enucleation.14 Our data was consistent with this 
ﬁ  nding although we had insufﬁ  cient power to demonstrate 
this conclusively, with a hazard ratio of 2.01 (95%CI 
0.74–5.52).
Some would argue that enucleation following PBRT is 
inevitable and that primary enucleation should be advocated 
instead. However, only a minority of our study population 
required enucleation. Survival outcome therefore should 
not be a reason for suggesting enucleation. An increased 
fractionation scheme or treatment with combination of 
radiation and angiogenic agents could decrease functional 
loss and enucleation.25
Zehetmayer launched a study using a stereotactic linear 
accelerator to avoid higher rate of enucleation, which is more 
convenient for delivery of fractionated treatment.18
Metastasis
Seven patients developed metastases during follow up. Higher 
and lower rates have been reported (Table 5).8,21,23,24,29,31 
Maximum tumor vertical height and accompanying retinal 
detachment have both been established as recognized risk 
factors for the development of metastatic disease in uveal 
melanoma.14 Our ﬁ  ndings support this data.
Despite tumor regression, most melanoma-related 
metastatic disease manifests within the ﬁ  rst ﬁ  ve years post-
treatment; 15,32,33 this ﬁ  nding is supported by our ﬁ  nding.
Six patients (7.9%) showed evidence of local recurrence 
following PBRT. This rate is in keeping with other literature 
reports.19 Recurrence in our patients was ﬁ  rst documented 0.5 
to 63 months post-treatment. There are reports demonstrating 
a lower incidence with earlier recurrence time.8,23,24 All six 
recurrent tumors in this study were large at diagnosis. All but 
one was located equatorially. The remaining was posteriorly 
located. These ﬁ  ndings are echoed in the literature.8
It is difficult to compare reported results referring 
to various radiation modalities because both dose and 
fractionation can be very different.31 Table 5 showed the 
least enucleation and metastasis rate in tumors (extra large 
or located too close to the optic nerve or fovea) treated with 
noninvasive linear accelerator-based stereotactic irradiation.31 
However, the prescribed radiation dose is higher than in the 
current study.
Other fractionation schedules might help to reduce the 
number of side effects without compromising local control.31 
It has now become possible to treat small to medium size 
ocular melanomas using stereotactic radiotherapy with 
acceptable dose distributions and target localizations. 
Stereotactic radiotherapy should provide a good alternative 
to proton therapy.34
Conclusions
Proton beam irradiation treatment was used in this study 
primarily for the management of large choroidal melanomas 
and those having failed previous alternative treatment(s). 
Almost all (97%) patients demonstrated a response to 
Table 5 Local control, metastasis, complications, and visual acuity after proton radiotherapy for uveal melanoma
Author(reference) Brovkina24 Gragoudas23 Conway21 Egger29 Dieckmann31 Current study
Dose (mean or range in Gy) 100–125 70 56 54.5 60–70 53.1
Follow-up (mean in months) 34 64 28 53.2 20^ 38.8
Recurrence (%) 19 3 33 1.9 2.2 14.5
Enucleation (%) 25 10 46 8.2 7.7 24
Metastasis (%) 6.3 20 10 12.3* 3.3 9.2
Cataract (%) – 42 28.6 – 18.9 20
Retinopathy (%) 5 – 9.5 – 25.5 39
Optic neuropathy (%) – – 9.5 – 20 16
Visual acuity (%  6/60) – 58 25 – – 26.3
Notes: *Ocular tumor-related death; ^Median.Clinical Ophthalmology 2009:3 55
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treatment and 87% showed successful control of tumor growth 
throughout the entire follow-up period with an associated 
statistically signiﬁ  cant reduction in MVTH post-treatment.
Best corrected visual acuity was markedly reduced 
(statistically significant) in the majority post treatment 
although notably those with inferotemporal, superonasal, 
and posterior pole tumors demonstrated an improvement in 
BCVA after treatment. Many patients required enucleation 
(24%), mainly due to refractory glaucoma. Less than 10% 
of patients developed clinically evident distant metastases 
during follow up, all involving the liver. This study 
demonstrated a statistically signiﬁ  cant association between 
increased risk of adverse event (enucleation, metastasis) and 
greater maximal basal tumor diameter.
In our experience, PBRT is a precise, effective, and 
reliable technique which achieves excellent tumor–normal 
tissue dose ratio. It is an effective mode (although very 
expensive)35,36 of treatment in the management of large and 
previously treated choroidal melanomas and is associated 
with low rates of enucleation over the short term.
Disclosure
The authors report no conﬂ  icts of interest in this work.
References
 1. Chiquet C, Grange JD, Ayzac L, et al. Effects of proton beam 
irradiation on uveal melanomas: a comparative study of Ki-67 expres-
sion in irradiated versus non-irradiated melanomas. Br J Ophthalmol. 
2000;84:98–102.
  2.  Gragoudas ES, Lane AM, Regan S, et al. A randomized controlled trial 
of varying radiation doses in the treatment of choroidal melanoma. Arch 
Ophthalmol. 2000;118:773–8.
  3.  Wright PK, Damato BE. Auditing outcomes after treatment of Scottish 
patients with uveal melanoma in Liverpool. J R Coll Surg Edinb. 
1999;44:260–4.
  4.  Mindel J, Finger P. Radiation therapy for choroidal melanoma. Thera-
peutic review. Surv Ophthamol. 1997;42:215–32.
 5. Melia BM, Abramson DH, Albert DM, et al. Collaborative Ocular 
Melanoma Study Group. Collaborative ocular melanoma study 
(COMS) randomized trial of I-125 brachytherapy for medium 
choroidal melanoma. I. Visual acuity after 3 years COMS report 
no. 16. Ophthalmology. 2001;108:348–66.
  6.  Gragoudas ES, Goitein M, Verhey L, et al. Proton beam irradiation-An 
alternative to enucleation for intraocular melanomas. Ophthalmology. 
1980;87:571–81.
  7.  Zimmerman LE, McLean IW, Foster WD. Does enucleation of the eye 
containing a malignant melanoma prevent or accelerate the dissemina-
tion of tumour cells. Br J Ophthalmol. 1978;62:420–5.
 8. Kodjikian L, Roy P, Rouberol F, et al. Survival after proton-beam 
irradiation of uveal melanomas. Am J Ophthalmol. 2004;137:1002–10.
  9.  Fine S. How should we manage a patient with uveal melanoma? Arch 
Ophthaloml. 1985;103:910–11.
10.  Spire M, Devouassoux MS, Kodjikian L, et al. Primary transpupillary 
thermotherapy for 18 small posterior pole uveal melanomas. 
Am J Ophthalmol. 2006;141:840–9.
11. Mueller AJ, Talies S, Schaller UC, et al. Stereotactic radiosurgery 
of large uveal melanomas with the gamma-knife. Ophthalmology. 
2000;107:1381–7.
12. Haas A, Pinter O, Papaefthymiou G, et al. Incidence of radiation 
retinopathy after high-dosage single-fraction gamma knife radiosurgery 
for choroidal melanoma Ophthalmology. 2002;109:909–13.
13.  Gragoudas ES, Goitein M, Koehler AM, et al. Proton irradia-
tion of small choroidal malignant melanomas. Am J Ophthalmol. 
1977;83:665–73.
14.  Foss AJE, Whelehan I, Hungerford JL, et al. Predictive factors for the 
development of rubeosis following proton beam radiotherapy for uveal 
melanoma. Br J Ophthalmol. 1997;81:748–54.
15. Kincaid MC, Forberg R, Torczynski E, et al. Complications after 
proton beam therapy for uveal malignant melanoma. A clinical and 
histopathologic study of ﬁ  ve cases. Ophthalmology. 1988;95:982–91.
16. Young LHY, Gragoudas ES. Macular uveal melanoma treated with 
proton beam irradiation. Retina. 1994;14:43–6.
17.  Tokuuye K, Akine Y, Sumi M, et al. Fractionated stereotactic radio-
therapy for choroidal melanoma. Radiother Oncol. 1997;43:87–91.
18. Zehetmayer M, Kitz K, Menapace R, et al. Local tumor control and 
morbidity after one to three fractions of stereotactic external beam 
irradiation for uveal melanoma. Radiother Oncol. 2000;55:135–44.
19. Wilkes SR, Gragoudas ES. Regression patterns of uveal melanomas 
after proton beam irradiation. Ophthalmology. 1982;89:840–4.
20.  Emara K, Weisbrod DJ, Sahgal A, et al. Stereotactic radiotherapy in the 
treatment of juxtapapillary choroidal melanoma: preliminary results. 
Int J Radiat Oncol Biol Phys. 2004;59:94–100.
21.  Conway RM, Poothullil AM, Daftari IK, et al. Estimates of ocular and 
visual retention following treatment of extra-large uveal melanomas by 
proton beam radiotherapy. Arch Ophthalmol. 2006;124:838–43.
22.  Gragoudas ES, Goitein M, Koehler A, et al. Proton beam irradiation 
of choroidal melanomas. Arch Ophthalmol. 1978;96:1583–91.
23.  Gragoudas ES, Seddon JM, Egan K . Long-term results of proton beam 
irradiated uveal melanomas. Ophthalmology. 1987;94:349–53.
24.  Brovkina AF, Zarubei GD. Ciliochoroidal melanomas treated with a 
narrow medical proton beam. Arch Ophthalmol. 1986;104:402–4.
25.  Gragoudas ES. Proton beam irradiation of uveal melanomas: the 
ﬁ  rst 30 years. The Weisenfeld Lecture. Invest Ophthalmol Vis Sci. 
2006;47:4666–73.
26.  Kim MK, Char DH, Castro JL, et al. Neovascular glaucoma 
after helium ion irradiation for uveal melanoma. Ophthalmology. 
1986;93:189–92.
27.  Gragoudas ES, Lane AM. Uveal melanoma: proton beam irradiation. 
Ophthalmol Clin North Am. 2005;18:111–18.
28.  Lee J, Logani S, Lakosha H, et al. Preretinal neovasculaisation associ-
ated with choroidal melanoma. Br J Ophthalmol. 2001;85:1309–12.
29.  Egger E, Zografos L, Schalenbourg A, et al. Eye retention after proton 
beam radiotherapy for uveal melanoma. Int J Radiat Oncol Biol Phys. 
2003;55:867–80.
30.  Egan KM, Gragoudas ES, Seddon JM, et al. The risk of enucleation 
after proton beam irradiation of uveal melanoma. Ophthalmology. 
1989;96:1377–82.
31. Dieckmann K, Georg D, Zehetmayer M, et al. LINAC based stereotactic 
radiotherapy of uveal melanoma: 4 years clinical experience. Radiother 
Oncol. 2003;67:199–206.
32. Robertson DM. A rationale for comparing radiation to enucleation 
in the management of choroidal melanoma. Am J Ophthalmol. 
1989;108:448–51.
33.  Li. W, Gragoudas ES, Egan KM. Tumor basal area and metastatic death 
after proton beam irradiation for choroidal melanoma. Arch Ophthalmol. 
2003;121:68–72.
34.  Jaywant SM, Osei EK, Ladak S. Stereotactic radiotherapy in the treat-
ment of ocular melanoma: A noninvasive eye ﬁ  xation aid and tracking 
system. J Appl Clin Med Phys. 2003;4:156–61.
35. Constable IJ. Proton irradiation therapy for ocular melanoma. Trans 
Opthalmol Soc U K. 1977;97:430.
36.  Gragoudas ES, Goitein M, Verhey L, et al. Proton beam irradiations 
of uveal melanomas. Arch Ophthalmol. 1982;100:928–34.